CYT 6091
Alternative Names: AURIMUNE; Aurimune-T; CYT-6091Latest Information Update: 28 Aug 2024
At a glance
- Originator CytImmune Sciences
- Class Antineoplastics; Tumour necrosis factors
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Injection)
- 23 Aug 2022 CYT 6091 is still in phase-I trials for Solid-tumours in USA (IV, Injection) (CytImmune Sciences pipeline, August 2022)
- 23 Aug 2022 National Cancer Institute (USA) enters into clinical trial agreement with CytImmune Sciences to conduct phase Ib and multiple phase II clinical trials prior to August 2022